Haiwei Mou

This study identifies TFAP2A as a driver of BRAF/MEK inhibitor resistance and immunosuppression, showing its disruption enhances antitumor immunity and overcomes drug resistance.

This study identifies drug-tolerant persister states in melanoma using MeRLin, showing their role in resistance and tumor recurrence.

The paper identifies the MYC-ATF4-ASS1 axis in melanoma that controls arginine synthesis and modulates immune responses, showing therapeutic potential with arginine depletors and BRAF/MEK inhibitors.

This study develops DR5-targeted CAR-T cells that kill solid tumors and MDSCs, enhance CD8+ T cell activity, and show minimal toxicity in preclinical models.

The paper shows that A-MYB activates TCFL5, which is essential for meiosis and spermiogenesis in placental mammals, and its loss causes sterility.